StockTipsArenaBeta

BUY Krishna Institute of Medical Sciences Limited — IDBI Capital

BUYKrishna Institute of Medical Sciences Limited

byIDBI CapitalHorizon: NA (inferred 1–3 months)17 Sept 2026via IDBI Capital Research Calls Telegram

Entry₹783Stated
Target₹846
Total upside +8.05%
Stop loss₹754-3.70% risk
CMP₹809.856h ago
Active+3.43%+4.46%upside left 3 mo left
Follow IDBI Capital for new calls(27% target hit, 131 closed calls)Get alertsWatch KIMS for new buy/sell callsGet alertsSee 1 other Short-term call on KIMSSee 70 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 18 Sept, 10:39 pm IST
8 supporting2 neutral0 opposing
Supports the BUY call (8)

MACD above its signal line — bullish momentum

Technicals · macd·18 Sept · today

KIMS enters O&M agreement to manage 183-bed Trust Hospital in Kakinada, Andhra Pradesh

NewsCnbc-Tv18·10 Sept · 1w ago

(opens in new tab)

Krishna Institute of Medical Sciences Ltd entered into an Operations and Management Agreement with Sarvottam Health Care Private Limited.

BSE · Company Update·10 Sept · 1w ago

(opens in new tab)

3 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·10 Sept · 1w ago

This hospital stock could hit ₹1,000 over the next 12 months, Investec predicts with a 'buy' rating

NewsCnbc-Tv18·3 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Indian Hospital Chains Expand Capacity Despite Staffing Crunch

NewsGoogle News·27 Aug · 3w ago

(opens in new tab)

KIMS to operate 250-bed Arete Hospital in Hyderabad under 5-year O&M deal

NewsCnbc-Tv18·20 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.